The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience
Metronomic chemotherapy inhibits tumor growth by continuous administration of lower-dose chemotherapy. Our study aimed to demonstrate the outcomes of metronomic chemotherapy with tegafur–uracil in locally advanced head and neck squamous cell carcinoma (LA HNSCC). This was a retrospective study inclu...
Main Authors: | Tsung-Jang Yeh, Leong-Perng Chan, Hui-Ting Tsai, Chin-Mu Hsu, Shih-Feng Cho, Mei-Ren Pan, Yi-Chang Liu, Chih-Jen Huang, Che-Wei Wu, Jeng-Shiun Du, Hui-Ching Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/10/2/168 |
Similar Items
-
Platinum Plus Tegafur–Uracil versus Platinum Alone during Concurrent Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A Propensity-Score-Matching Analysis
by: Ching-Feng Lien, et al.
Published: (2022-09-01) -
Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
by: Sheng‐Kai Liang, et al.
Published: (2023-09-01) -
Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
by: Po-Huang Chen, et al.
Published: (2022-12-01) -
Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
by: Yung-Sung Yeh, et al.
Published: (2017-04-01) -
Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
by: Azim HA, et al.
Published: (2018-11-01)